Loading…
Cognition Therapeutics, Inc. is projected to rise to $1.28 by 2027, a +17% move from its current price of $1.09. CGTX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $1.03 | $1.09 | $1.16 | +0.11% |
| Jul 13 | $1.01 | $1.09 | $1.18 | +0.23% |
| Jul 14 | $0.9906 | $1.09 | $1.21 | +0.35% |
| Jul 15 | $0.9767 | $1.10 | $1.23 | +0.46% |
| Jul 16 | $0.9647 | $1.10 | $1.25 | +0.58% |
| Jul 17 | $0.9541 | $1.10 | $1.26 | +0.69% |
| Jul 18 | $0.9445 | $1.10 | $1.28 | +0.81% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.9445 | $1.10 | $1.28 | +0.81% |
| Week 2 | $0.8943 | $1.11 | $1.37 | +1.62% |
| Week 3 | $0.8592 | $1.12 | $1.45 | +2.44% |
| Week 4 | $0.8317 | $1.13 | $1.52 | +3.27% |
| Week 5 | $0.809 | $1.13 | $1.59 | +4.10% |
| Week 6 | $0.7896 | $1.14 | $1.66 | +4.94% |
| Week 7 | $0.7727 | $1.15 | $1.72 | +5.79% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company that engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its focus includes protecting neuronal synapses by preventing the binding of oligomers of pathogenic proteins, with lead candidate zervimesine described as an orally delivered small molecule in Phase 2 studies for Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies.
Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York, operating within the Healthcare sector.
CGTX is the publicly traded equity of Cognition Therapeutics, Inc. Its current price is $1.13, its market capitalization is $101.13M, and it holds a rank of 4199.
The near-term technical picture shows neutral sentiment with RSI(14) at 40, the 50-day moving average at $1.24 and the 200-day moving average at $1.36. Support sits at $1.02 and resistance sits at $1.68. The 30-day price range spans from $0.6995 to $1.83, indicating notable near-term volatility.
A major floor 45.4% below — a decisive break under it would weaken the trend.
The nearest floor, 6.4% below — buyers have tended to step in here.
The nearest ceiling, 54.1% above — a clean break opens room to run.
A major ceiling 76.5% above — clearing it would confirm fresh momentum.
Key CGTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CGTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.08 | Buy | $1.09 | Sell |
| MA 10 | $1.11 | Sell | $1.13 | Sell |
| MA 20 | $1.21 | Sell | $1.17 | Sell |
| MA 50 | $1.22 | Sell | $1.19 | Sell |
| MA 100 | $1.13 | Sell | $1.20 | Sell |
| MA 200 | $1.32 | Sell | $1.20 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.31 | Neutral |
| Stoch RSI (14) | 12.59 | Buy |
| CCI (20) | -59.82 | Neutral |
| Williams %R (14) | -89.39 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -33.94 | Sell |
| Bollinger %B (20,2) | 0.33 | Neutral |
| Stochastic %K (14) | 10.61 | Buy |
| TRIX (15) | -0.29 | Sell |
| Awesome (5,34) | -0.15 | Sell |
| Ultimate (7,14,28) | 37.17 | Neutral |
| Momentum (10) | -0.04 | Sell |
| Aroon Osc (25) | -8.00 | Sell |
| Hull MA (9) | 1.07 | Buy |
| ADX (14) | 13.99 | Neutral |
| ATR (14) | 0.06 | Info |
Near-term sentiment is NEUTRAL with RSI(14) at 40. The stock trades above the SMA50 of $1.24 but below the SMA200 of $1.36, suggesting a mixed intermediate trend.
Key levels to watch are support at $1.02 and resistance at $1.68, marking potential turning points in the near term. The 30-day range runs from $0.6995 to $1.83, reflecting a broad trading band and ongoing volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.595 | $1.09 | $1.68 | 0% | Neutral | |
| $0.926 | $1.28 | $1.90 | +17% | Neutral | |
| $0.801 | $1.17 | $1.86 | +8% | Neutral | |
| $1.14 | $1.77 | $2.95 | +62% | Bullish | |
| $1.41 | $2.28 | $3.95 | +109% | Bullish | |
| $1.67 | $2.82 | $5.06 | +158% | Bullish | |
| $2.00 | $3.53 | $6.55 | +224% | Bullish | |
| $1.85 | $3.40 | $6.47 | +212% | Bullish | |
| $1.91 | $3.65 | $7.12 | +235% | Bullish | |
| $1.94 | $3.84 | $7.68 | +253% | Bullish | |
| $3.33 | $7.41 | $16.26 | +580% | Bullish | |
| $6.25 | $13.89 | $31.95 | +11.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.595 | $1.09 | $1.33 | +0.00% |
| August 2026 | $0.9572 | $1.16 | $1.46 | +6.42% |
| September 2026 | $0.9848 | $1.21 | $1.56 | +4.34% |
| October 2026 | $0.944 | $1.17 | $1.54 | -2.98% |
| November 2026 | $0.9449 | $1.19 | $1.58 | +1.14% |
| December 2026 | $0.9824 | $1.25 | $1.68 | +4.99% |
Click any year to see its month-by-month CGTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Cognition Therapeutics, Inc.'s 2026 outlook centres on $1.09, within a $0.595 to $1.68 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, CGTX could reach as high as $1.90, with a base case around $1.28 and support toward $0.926 — roughly +17% from $1.09. Price action looks broadly range-bound.
Expect CGTX to range from $0.801 to $1.86 through 2028. The $1.17 average target implies a +8% move from current prices. That is -8% versus the projected 2027 average. A consolidation phase looks the most probable path here.
The CGTX price prediction for 2029 points to an average of $1.77 (low $1.14, high $2.95) — a potential gain of +62% on today's $1.09. Momentum favours further upside here.
In 2030, CGTX is projected to trade between $1.41 and $3.95, averaging $2.28 — a potential gain of +109% from today's $1.09. That is up +29% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Cognition Therapeutics, Inc.'s 2031 outlook centres on $2.82, within a $1.67 to $5.06 range. That is up +24% on the projected 2030 average. That marks a +158% change versus current levels. Momentum favours further upside here.
By 2032, CGTX could reach as high as $6.55, with a base case around $3.53 and support toward $2.00 — roughly +224% from $1.09. Buyers look set to stay in control over this stretch.
Expect CGTX to range from $1.85 to $6.47 through 2033. The $3.40 average target implies a +212% move from current prices. That is -4% versus the projected 2032 average. Momentum favours further upside here.
The CGTX price prediction for 2034 points to an average of $3.65 (low $1.91, high $7.12) — a potential gain of +235% on today's $1.09. Buyers look set to stay in control over this stretch.
In 2035, CGTX is projected to trade between $1.94 and $7.68, averaging $3.84 — a potential gain of +253% from today's $1.09. That is up +5% on the projected 2034 average. Momentum favours further upside here.
Cognition Therapeutics, Inc.'s 2040 outlook centres on $7.41, within a $3.33 to $16.26 range. That is up +93% on the projected 2035 average. That marks a +580% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, CGTX could reach as high as $31.95, with a base case around $13.89 and support toward $6.25 — roughly +11.7x from $1.09. Momentum favours further upside here.
Investing $1,000 in CGTX today (≈ 917.431193 CGTX) could be worth
$12,744.16
+$11,744.16 (+1174%) by 2050 · US Dollar
Based on the average projected CGTX price of $13.89 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CGTXwould be worth at today's price.
$1,000 invested in CGTX on Jul 10, 2025 (≈ 1,428.571453 CGTX) would be worth
$1,557.14
+$557.14 (+55.7%) today · 1.56× · US Dollar
Based on a CGTX entry price of $0.7 vs. today's $1.09.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.17 | $931.62 | -6.8% |
| 1 month ago | $1.14 | $956.14 | -4.4% |
| 3 months ago | $0.905 | $1,204.42 | +20.4% |
| 6 months ago | $1.47 | $741.5 | -25.9% |
| 1 year ago | $0.7 | $1,557.14 | +55.7% |
| All time (4.8y) ago | $12.77 | $85.36 | -91.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CGTX forecast.
Our base-case forecast reaches $2.20 around 2030.
Implied market cap at $2.20: $196.9M
The multi-year forecast shows a bullish shift beginning in 2029 and continuing through 2050. The 2029 forecast lists an average price of $1.84 with a min of $1.19 and a max of $3.08, and a bullish sentiment. In 2030 the average price rises to $2.31 with a min of $1.42 and a max of $4.01, for an ROI of 104.1 and a bullish stance.
The 2031–2032 horizon continues this ascent with averages of $2.93 and $3.64 and ROIs of 159.5 and 222, respectively, all labeled bullish.
Beyond the early 2030s, the path stays bullish with 2033 at $3.43 average (ROI 203.6), 2034 at $3.78 (234.5), and 2035 at $3.90 (245.2). The long-range view shows dramatic upside later, with 2040 averaging $7.78 (588.2) and 2050 averaging $13.71 (1113.5), both bullish. These figures are estimates and not guarantees, and outcomes depend on a range of factors.
Note the forecast implies higher volatility and longer-horizon upside potential, consistent with the asset’s profile and market dynamics.
Tap a question to reveal the answer.
2030 average price is $2.31, with a min of $1.42 and a max of $4.01. The ROI is 104.1 and the sentiment is BULLISH.
The forecast shows a bullish sentiment from 2029 onward, with 2029 average $1.84, 2030 average $2.31 and 2050 average $13.71. ROIs include 63 in 2029, 104.1 in 2030, 159.5 in 2031, 222 in 2032 and up to 1113.5 by 2050. These are estimates, not guarantees.
Yes. The forecast shows a max of $5.28 in 2031, a max of $6.75 in 2032, a max of $6.54 in 2033, and a max of $7.39 in 2034, with higher forwards—$17.08 max in 2040 and $31.54 max in 2050.
Current price is $1.13 and market cap is $101.13M.
Sentiment is NEUTRAL with RSI(14) at 40. SMA50 is $1.24 and SMA200 is $1.36. Support is $1.02 and resistance is $1.68. The 30-day range is $0.6995 to $1.83.
Cognition Therapeutics, Inc. Community Discussion
0Share your Cognition Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.